Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
What Patients With CLL/SLL Should Know About the FDA's Approval of Calquence
November 28th 2019The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.
Read More
What You Need to Know About the FDA's Approval of Zejula
November 1st 2019The Food and Drug Administration’s recent approval of Zejula for certain patients with advanced ovarian, fallopian tube or primary peritoneal cancer was the first PARP inhibitor approved for the treatment, not the maintenance, of these women.
Read More
Half of Patients With Breast Cancer Say Transportation Costs Are a Challenge to Treatment
October 29th 2019Forty-eight percent of those surveyed by The Pink Fund said the cost of transportation was a barrier to receiving treatment and 60% missed an appointment or were late to one because of transportation issues.
Read More
Live for Today: One Testicular Cancer Survivor's Journey to Advocacy
October 24th 2019In this episode of the “CURE Talks Cancer” podcast, we spoke with Scott Petinga, who was diagnosed with and overtreated for his stage 1 testicular cancer, about his journey and how he now advocates for other patients.
Read More
Metastatic Breast Cancer Alliance Empowers Patients to Learn About Clinical Trials
October 22nd 2019The Metastatic Breast Cancer Alliance (MBCA) launched a campaign to bring awareness of clinical trials to more individuals and encourage them to speak with their health care teams about them.
Read More
Targeting DNA Repair Pathways With Lynparza May Delay Prostate Cancer Progression
October 3rd 2019Phase 3 trial findings showed that treatment with Lynparza delayed disease progression by about four months compared with newer hormonal agents in pre-treated patients with metastatic castration-resistant prostate cancer and faulty DNA repair genes.
Read More
Addition of CDK4/6 Inhibitors to Faslodex Improves Survival in Breast Cancer Subgroup
September 30th 2019Two studies showed that adding a CDK4/6 inhibitor to treatment with Faslodex improved survival among women with hormone receptor-positive, human epidermal growth factor2-negative advanced breast cancer.
Read More
Frontline Tagrisso Improves Survival Among Specific Subgroup of Patients with NSCLC
September 30th 2019First-line Tagrisso significantly extended overall survival compared with first generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer, according to results from the phase 3 FLAURA study.
Read More